Parallax Volatility Advisers
ENTA icon

Parallax Volatility Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Parallax Volatility Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-835
Closed -$80K – 2816
2019
Q1 		$80K Buy
+835
New +$74.9K ﹤0.01% 2171
2018
Q1 		– Sell
-2,352
Closed -$138K – 2724
2017
Q4 		$138K Buy
+2,352
New +$118K ﹤0.01% 2572

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallax Volatility Advisers's ENTA Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 835 shares — an estimated $80K sold.

Parallax Volatility Advisers first reported a position in ENTA in Q4 2017 and held it in 2 quarters. The position peaked at $138K in Q4 2017. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Parallax Volatility Advisers reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 835 Enanta Pharmaceuticals shares in Q2 2019, an estimated $80K.
  • Parallax Volatility Advisers first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Enanta Pharmaceuticals position peaked at $138K in Q4 2017.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.